Barton A Kamen

Summary

Affiliation: New Jersey
Country: USA

Publications

  1. ncbi "The odds are all or none!" An account of one family's Odyssey more than a half century ago
    Barton A Kamen
    Department of Pediatrics and Pharmacology, Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ, USA
    J Pediatr Hematol Oncol 30:505-6. 2008
  2. ncbi Marker turned target? A case to review neprilysin in ALL (or lessons learned at the American Association for Cancer Research Meetings, 2006)
    Barton A Kamen
    Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08901, USA
    J Pediatr Hematol Oncol 28:201-2. 2006
  3. ncbi Metronomic therapy from a pharmacologist's view
    Barton A Kamen
    Robert Wood Johnson Medical School, 195 Little Albany Street, New Brunswick, NJ, USA
    J Pediatr Hematol Oncol 28:325-7. 2006
  4. ncbi What is learned from an acronym? Convergence of treatments and/or diseases?
    Barton A Kamen
    Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA
    J Pediatr Hematol Oncol 29:277-8. 2007
  5. ncbi L'asparaginase and methotrexate combinations: clashes of empiric success and laboratory models?
    Barton A Kamen
    Robert Wood Johnson Medical School, 195 Little Albany Street, New Brunswick, New Jersey 08901, USA
    J Pediatr Hematol Oncol 29:587-8. 2007
  6. ncbi High-dose methotrexate: insecure rationale: take 2
    Barton A Kamen
    Robert Wood Johnson Medical School, New Brunswick, NJ, USA
    J Pediatr Hematol Oncol 30:639-40. 2008
  7. ncbi A review of folate receptor alpha cycling and 5-methyltetrahydrofolate accumulation with an emphasis on cell models in vitro
    Barton A Kamen
    Cancer Institute of New Jersey, Robert Wood Johnson Medical School, 195 Little Albany Street, New Brunswick, NJ 80901, USA
    Adv Drug Deliv Rev 56:1085-97. 2004
  8. ncbi Phase 2B trial of aminopterin in multiagent therapy for children with newly diagnosed acute lymphoblastic leukemia
    Peter D Cole
    Pediatric Hematology Oncology, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School UMDNJ, 195 Little Albany Street, New Brunswick, NJ 08901, USA
    Cancer Chemother Pharmacol 62:65-75. 2008
  9. ncbi High-performance liquid chromatography separation of aminopterin-polyglutamates within red blood cells of children treated for acute lymphoblastic leukemia
    Veena Vijayanathan
    Pediatric Hematology Oncology, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School UMDNJ, New Brunswick, NJ, USA
    Transl Res 150:367-73. 2007
  10. ncbi Pharmacodynamic properties of methotrexate and Aminotrexate during weekly therapy
    Peter D Cole
    Department of Pediatric Hematology Oncology, The Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey, NJ 08901, USA
    Cancer Chemother Pharmacol 57:826-34. 2006

Collaborators

Detail Information

Publications36

  1. ncbi "The odds are all or none!" An account of one family's Odyssey more than a half century ago
    Barton A Kamen
    Department of Pediatrics and Pharmacology, Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ, USA
    J Pediatr Hematol Oncol 30:505-6. 2008
  2. ncbi Marker turned target? A case to review neprilysin in ALL (or lessons learned at the American Association for Cancer Research Meetings, 2006)
    Barton A Kamen
    Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08901, USA
    J Pediatr Hematol Oncol 28:201-2. 2006
  3. ncbi Metronomic therapy from a pharmacologist's view
    Barton A Kamen
    Robert Wood Johnson Medical School, 195 Little Albany Street, New Brunswick, NJ, USA
    J Pediatr Hematol Oncol 28:325-7. 2006
  4. ncbi What is learned from an acronym? Convergence of treatments and/or diseases?
    Barton A Kamen
    Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA
    J Pediatr Hematol Oncol 29:277-8. 2007
  5. ncbi L'asparaginase and methotrexate combinations: clashes of empiric success and laboratory models?
    Barton A Kamen
    Robert Wood Johnson Medical School, 195 Little Albany Street, New Brunswick, New Jersey 08901, USA
    J Pediatr Hematol Oncol 29:587-8. 2007
  6. ncbi High-dose methotrexate: insecure rationale: take 2
    Barton A Kamen
    Robert Wood Johnson Medical School, New Brunswick, NJ, USA
    J Pediatr Hematol Oncol 30:639-40. 2008
  7. ncbi A review of folate receptor alpha cycling and 5-methyltetrahydrofolate accumulation with an emphasis on cell models in vitro
    Barton A Kamen
    Cancer Institute of New Jersey, Robert Wood Johnson Medical School, 195 Little Albany Street, New Brunswick, NJ 80901, USA
    Adv Drug Deliv Rev 56:1085-97. 2004
    ..This chapter reviews much of this work and compares and contrasts it to studies of other cells, both normal and malignant...
  8. ncbi Phase 2B trial of aminopterin in multiagent therapy for children with newly diagnosed acute lymphoblastic leukemia
    Peter D Cole
    Pediatric Hematology Oncology, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School UMDNJ, 195 Little Albany Street, New Brunswick, NJ 08901, USA
    Cancer Chemother Pharmacol 62:65-75. 2008
    ..This current trial was done to document the toxicity of the aminopterin within a multiagent therapeutic regimen for children with newly diagnosed ALL...
  9. ncbi High-performance liquid chromatography separation of aminopterin-polyglutamates within red blood cells of children treated for acute lymphoblastic leukemia
    Veena Vijayanathan
    Pediatric Hematology Oncology, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School UMDNJ, New Brunswick, NJ, USA
    Transl Res 150:367-73. 2007
    ..As AMT continues to be tested in clinical trials, the methods described here will be useful to define relationships between clinical response to AMT and RBC accumulation of AMT-polyglutamates...
  10. ncbi Pharmacodynamic properties of methotrexate and Aminotrexate during weekly therapy
    Peter D Cole
    Department of Pediatric Hematology Oncology, The Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey, NJ 08901, USA
    Cancer Chemother Pharmacol 57:826-34. 2006
    ....
  11. ncbi Phase II trial of oral aminopterin for adults and children with refractory acute leukemia
    Peter D Cole
    Department of Pediatric Oncology, The Cancer Institute of New Jersey, New Brunswick, New Jersey 08901, USA
    Clin Cancer Res 11:8089-96. 2005
    ....
  12. ncbi Dextromethorphan is effective in the treatment of subacute methotrexate neurotoxicity
    Richard A Drachtman
    Cancer Institute of New Jersey Robert Wood Johnson Medical School, New Brunswick 08816, USA
    Pediatr Hematol Oncol 19:319-27. 2002
    ..These data provide support for a placebo-controlled clinical trial to examine the ability of DM to prevent or alleviate MTX-Ntox...
  13. ncbi Osteosarcoma cells, resistant to methotrexate due to nucleoside and nucleobase salvage, are sensitive to nucleoside analogs
    Peter D Cole
    Department of Pediatrics, The Cancer Institute of NJ Robert Wood Johnson Medical School, 195 Little Albany Street, New Brunswick, NJ 08901, USA
    Cancer Chemother Pharmacol 50:111-6. 2002
    ..To test a novel strategy for overcoming intrinsic resistance to methotrexate (MTX) in osteosarcoma (OS) due to nucleoside and nucleobase salvage (NS)...
  14. ncbi Delayed neurotoxicity associated with therapy for children with acute lymphoblastic leukemia
    Peter D Cole
    Department of Pediatrics and Pharmacology, Robert Wood Johnson Medical School UMDNJ, The Cancer Institute of New Jersey, New Brunswick, New Jersey 08901, USA
    Ment Retard Dev Disabil Res Rev 12:174-83. 2006
    ..Finally, we suggest testable strategies to ameliorate the symptoms of treatment-related neurotoxicity or decrease its incidence...
  15. ncbi "Beriberi" interesting!
    Peter D Cole
    Robert Wood Johnson Medical School/UMDNJ, New Brunswick, New Jersey, USA
    J Pediatr Hematol Oncol 25:924-6. 2003
  16. ncbi Steroid-induced alterations of mood and behavior in children during treatment for acute lymphoblastic leukemia
    Carl J Hochhauser
    The Institute for the Study of Child Development, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, 97 Paterson Street, New Brunswick, NJ, 08903, USA
    Support Care Cancer 13:967-74. 2005
    ..In addition, we review recent data to indicate how concurrent use of antifolates may place these children at particular risk for adverse psychological reactions...
  17. ncbi Megadose methylprednisolone therapy: 2 decades of experience and empiric success in need of explanation, validation, and exploitation
    Barton A Kamen
    Robert Wood Johnson Medical School, New Brunswick, NJ, USA
    J Pediatr Hematol Oncol 29:211-2. 2007
  18. ncbi Methotrexate polyglutamation may lack prognostic significance in children with B-cell precursor acute lymphoblastic leukemia treated with intensive oral methotrexate
    Elpis Mantadakis
    Pediatric Hematology/Oncology Clinic, PEPAGNI University Hospital of Iraklio, Crete, Greece
    J Pediatr Hematol Oncol 24:636-42. 2002
    ..CONCLUSIONS: In the context of effective prolonged divided-dose oral methotrexate-based therapy in the treatment of BCP-ALL, methotrexate accumulation and polyglutamation no longer seem to have prognostic significance...
  19. ncbi Systemic methotrexate exposure is greater after intrathecal than after oral administration
    Bruce C Bostrom
    Department of Pediatric Hematology Oncology, Children s Hospitals and Clinics, Minneapolis, Minnesota, USA
    J Pediatr Hematol Oncol 25:114-7. 2003
    ..To compare systemic exposure after intrathecal and oral methotrexate administration...
  20. ncbi Reduced folate carrier mutations are not the mechanism underlying methotrexate resistance in childhood acute lymphoblastic leukemia
    Yotam Kaufman
    Department of Biology, The Technion, Haifa, Israel
    Cancer 100:773-82. 2004
    ..This is the first study of RFC mutations in multiple pediatric leukemia specimens...
  21. ncbi O (4)-benzylfolic acid inactivates O (6)-alkylguanine-DNA alkyltransferase in brain tumor cell lines
    Stewart P Johnson
    Department of Surgery, Duke University Medical Center, Box 2616, Durham, NC 27710, USA
    Cancer Chemother Pharmacol 60:883-9. 2007
    ..Previous studies have suggested that uptake of O(4)-BFA is mediated by the folate receptor (FR), and, thus, its use may be limited to cells expressing FR...
  22. ncbi Metronomic therapy: it makes sense and is patient friendly
    Barton A Kamen
    J Pediatr Hematol Oncol 27:571-2. 2005
  23. ncbi High-dose methotrexate and asparaginase for the treatment of children with acute lymphoblastic leukemia: why and how?
    Barton A Kamen
    J Pediatr Hematol Oncol 26:333-5. 2004
  24. ncbi High-dose methotrexate in acute lymphoblastic leukemia: where is the evidence for its continued use?
    Elpis Mantadakis
    Department of Pediatric Hematology Oncology, University Hospital of Heraklion, Crete, Greece
    Pharmacotherapy 25:748-55. 2005
    ..Despite its extensive use, high-dose intravenous methotrexate has not been proved conclusively to be more effective than less toxic, less labor intensive, and less costly methods of methotrexate administration...
  25. ncbi The anti-angiogenic basis of metronomic chemotherapy
    Robert S Kerbel
    Molecular and Cellular Biology Research, Sunnybrook and Women's College Health Sciences Centre, S-217, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada
    Nat Rev Cancer 4:423-36. 2004
  26. ncbi On maintaining the honor and sanctity of our profession: reflections and personal trials and a book review: sustaining the dignity and nobility of medical care
    Barton A Kamen
    J Pediatr Hematol Oncol 30:187-8. 2008
  27. ncbi 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICA-riboside) as a targeting agent for therapy of patients with acute lymphoblastic leukemia: are we there and are there pitfalls?
    Bruce N Cronstein
    NYU School of Medicine, New York, New York, USA
    J Pediatr Hematol Oncol 29:805-7. 2007
  28. ncbi Effects of folate and folylpolyglutamyl synthase modulation on chemosensitivity of breast cancer cells
    Robert C Cho
    Department of Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada
    Mol Cancer Ther 6:2909-20. 2007
    ..Whether or not FPGS modulation may be an important clinical determinant of chemosensitivity of breast cancer cells to 5FU and methotrexate-based chemotherapy needs further exploration...
  29. ncbi What is the price of an erythrocyte and neutrophil?
    Barton A Kamen
    J Pediatr Hematol Oncol 26:699-700. 2004
  30. ncbi Targeting Ras signaling through inhibition of carboxyl methylation: an unexpected property of methotrexate
    Ann M Winter-Vann
    Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710, USA
    Proc Natl Acad Sci U S A 100:6529-34. 2003
    ..These results suggest that inhibition of Icmt is a critical component of the antiproliferative effect of methotrexate, expanding our understanding of this widely used drug and identifying Icmt as a target for drug discovery...
  31. ncbi The bullseye of cancer therapy: a moving target
    Philip Frost
    Curr Opin Pharmacol 3:335-7. 2003
  32. ncbi Prologue to Ignorance is the Greatest Risk
    Barton A Kamen
    J Pediatr Hematol Oncol 27:121. 2005
  33. ncbi L-asparaginase: old dog, more tricks and leukemia: not simply a liquid tumor
    Barton A Kamen
    J Pediatr Hematol Oncol 27:243. 2005
  34. ncbi Food for thought: homage to a versatile vitamin: lessons learned from nature and your mother "eat your spinach!"
    Barton A Kamen
    J Pediatr Hematol Oncol 27:347-8. 2005
  35. ncbi The solutions for one generation may become the problems of the next
    Barton A Kamen
    J Pediatr Hematol Oncol 26:79-80. 2004
  36. ncbi High time for low-dose prospective clinical trials
    Robert S DiPaola
    Cancer 98:1559-61. 2003